China SXT Pharmaceuticals, Inc. (SXTC) Gross margin 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) gross margin by fiscal year — reported gross profit divided by reported revenue.
21.9%FY2026 · since FY2017: 47.4% → 21.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 21.9% | +0.7 pp |
| FY2025 | 21.1% | -7.6 pp |
| FY2024 | 28.7% | +7.1 pp |
| FY2023 | 21.6% | -26.5 pp |
| FY2022 | 48.1% | -11.3 pp |
| FY2021 | 59.4% | +7.1 pp |
| FY2020 | 52.4% | -13.4 pp |
| FY2019 | 65.8% | +17.3 pp |
| FY2018 | 48.5% | +1.1 pp |
| FY2017 | 47.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice